Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATCH Subprotocol Q: Ado-trastuzumab Emtansine in HER2-Amplified Tumors
NCT04439110Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2015
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab emtansine in lymphoma, refractory malignant solid neoplasm, multiple myeloma (MM), sponsored by National Cancer Institute. Started Aug 2015; status: active, not recruiting.
02
Drugs
trastuzumab emtansine
03
Conditions
lymphomarefractory malignant solid neoplasmmultiple myeloma (MM)
Beyond the preview
Go deeper on NCT04439110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04439110.